Ovid Therapeutics
OVID
OVID
60 hedge funds and large institutions have $71.7M invested in Ovid Therapeutics in 2022 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 11 increasing their positions, 22 reducing their positions, and 8 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
60
Holders Change
+1
Holders Change %
+1.69%
% of All Funds
0.97%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
%
% of All Funds
0.02%
New
9
Increased
11
Reduced
22
Closed
8
Calls
$17K
Puts
–
Net Calls
+$17K
Net Calls Change
-$35K
Top Buyers
| 1 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$4.3M |
| 2 |
MAP
Madison Avenue Partners
New York
|
+$2.47M |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$309K |
| 4 |
E
Ergoteles
New York
|
+$141K |
| 5 |
Jane Street
New York
|
+$83.8K |
Top Sellers
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$2.84M |
| 2 |
BlackRock
New York
|
-$809K |
| 3 |
D.E. Shaw & Co
New York
|
-$344K |
| 4 |
Bank of New York Mellon
New York
|
-$261K |
| 5 |
DA
DCF Advisers
Greenwich,
Connecticut
|
-$172K |
